ABSTRACT ROS1 fusion-positive non–small cell lung cancer (NSCLC), occurring in 1–2% of patients, represents a rare but clinically important subset. Patients with ROS1 fusion-positive NSCLC are often younger and tend to have little or no history of smoking. Current first-generation tyrosine kinase inhibitors (TKIs) such...
M. Nagasaka, C. Park, Z. Arter et al.· Future Oncology· 0 citations
Small cell lung cancer (SCLC) remains one of the most lethal thoracic malignancies, characterized by rapid progression, early metastasis, and limited durable responses to conventional therapy. Delta-like ligand 3 (DLL3), a Notch pathway inhibitory ligand aberrantly overexpressed on the surface of approximately 70-85% o...
Vivian Tieu, Z. Arter, M. Nagasaka· Cancer Treatment Reviews· 0 citations
86
Background:
Major advances in HIV and cancer care have occurred over the past two decades, but whether outcomes for people living with HIV (PLHIV) with cancer have improved remains uncertain. We evaluated palliative care utilization, hospitalization burden, and survival across predefined calendar eras from 2...
K. A. Aldecoa, Chef Stan L. Macaraeg, Misako Nagasaka et al.· JCO Oncology Practice· 0 citations
Loss of methylthioadenosine phosphorylase (MTAP), which occurs in approximately 10-15% of non-small-cell lung cancers and other solid tumors, represents a key synthetic-lethal vulnerability linking tumor metabolism to epigenetic regulation. MTAP deletion disrupts the methionine salvage pathway, leading to accumulation...
Z. Arter, Joo Sung Shim, C. Park et al.· Cancer Treatment Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.